Comparison of serum Concentration of Se, Pb, Mg, Cu, Zn, between MS patients and healthy controls

Authors

  • Mohsen Foroughipour Professor of Neurology, Department of Neurology, Mashhad University of Medical Sciences, Mashhad, Iran

Keywords:

Multiple sclerosis, Zinc, Lead, Copper, Magnesium, Selenium

Abstract

Introduction: Multiple Sclerosis (MS) is defined as one of the inflammatory autoimmune disorders and is common. Its exact etiology is unclear. There are some evidences on the role of environmental factors in susceptible genetics. The aim of this study is to evaluate the possible role of Selenium, Zinc, Copper, Lead and Magnesium metals in Multiple Sclerosis patients. 

Methods: In the present analytical cross-sectional study, 56 individuals including 26 patients and 30 healthy controls were enrolled in the evaluation. The serum level of Se, Zn, Cu, Pb were quantified in graphite furnace conditions and flame conditions by utilizing an atomic absorption Perkin Elmer spectrophotometer 3030. The serum levels of Mg  were measured by auto analyzer 1500 BT. The mean level of minerals (Zn, Pb, Cu, Mg, Se) in serum samples were compared in both cases and controls. The mean level of minerals (Zn, Pb, Cu, Mg, Se) in serum samples were compared in both cases and controls by using independent-samples t-test for normal distribution and Mann-Whitney U test as a non-parametric test . All statistical analyses were carried out using SPSS 11.0.

Results: As well as the Zn, Cu, and Se, there was no significant difference between MS patients and healthy individuals in Pb concentrations (p-value = 0.11, 0.14, 0.32, 0.20 respectively) but the level of Mg was significantly different (p= 0.001).

Conclusion: All serum concentrations of Zn, Pb, Se, Cu in both groups were in normal ranges and there was no difference in MS patients compared with the healthy group who were matched in genetics. Blood level of Mg was significantly lower in MS patients. But it should be noted that even with the low level of serum magnesium in MS patients, this value is still in the normal range.

References

Bradley WG Robert B. Daroff, Jankovic J, John C, Mazziotta, Pomeroy SL. Neurology in clinical practice:

principles of diagnosis and management: Taylor & Francis; 2004.

Sahraian MA, Khorramnia S, Ebrahim MM, Moinfar Z, Lotfi J, Pakdaman H. Multiple sclerosis in Iran: a

demographic study of 8,000 patients and changes over time. Eur Neurol. 2010; 64(6): 331-6. doi:

1159/000321649. PMID: 21071949.

Elhami SR, Mohammad K, Sahraian MA, Eftekhar H. A 20-year incidence trend (1989-2008) and point

prevalence (March 20, 2009) of multiple sclerosis in Tehran, Iran: a population-based study.

Neuroepidemiology. 2010; 36(3): 141-7. doi: 10.1159/000324708. PMID: 21508646.

Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann

Neurol. 2007; 61(4): 288-99. doi: 10.1002/ana.21117. PMID: 17444504.

Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors.

Ann Neurol. 2007; 61(6): 504-13. doi: 10.1002/ana.21141. PMID: 17492755.

Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of

multiple sclerosis. Jama. 2006; 296(23): 2832-8. doi: 10.1001/jama.296.23.2832. PMID: 17179460.

Riise T, Nortvedt MW, Ascherio A. Smoking is a risk factor for multiple sclerosis. Neurology. 2003; 61(8):

-4 .doi: 10.1212/01.WNL.0000081305.66687.D2. PMID: 14581676.

Ozgocmen S, Bulut S, Ilhan N, Gulkesen A, Ardicoglu O, Özkan Y. Vitamin D deficiency and reduced

bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J Bone

Miner Metab. 2005; 23(4): 309-13. doi: 10.1007/s00774-005-0604-9. PMID: 15981027.

Munger KL, Zhang SM, O'Reilly E, Hernán MA, Olek MJ, Willett WC, et al. Vitamin D intake and

incidence of multiple sclerosis. Neurology. 2004; 62(1): 60-5. doi:

1212/01.WNL.0000101723.79681.38. PMID: 14718698.

Payne A. Nutrition and diet in the clinical management of multiple sclerosis. J Hum Nutr Diet. 2001; 14(5):

-57. doi: 10.1046/j.1365-277X.2001.00308.x. PMID: 11906575.

Hutter CD, Laing P. Multiple sclerosis: sunlight, diet, immunology and aetiology. Med Hypotheses. 1996;

(2): 67-74. doi: 10.1016/S0306-9877(96)90002-X. PMID: 8692046.

Schwarz S, Leweling H. Multiple sclerosis and nutrition. Mult Scler. 2005; 11(1): 24-32. doi:

1191/1352458505ms1119oa. PMID: 15732263.

Lauer K. Diet and multiple sclerosis. Neurology. 1997; 49(Suppl 2): 55-61. doi: 10.1212/WNL.49.2-Suppl- 2.S55.

Smith DK, Feldman EB, Feldman DS. Trace element status in multiple sclerosis. Am J Clin Nutr. 1989;

(1): 136-40. PMID: 2750686.

Gould C, Warren H. Trace elements in human biology and a preliminary report on a possible relationship to

multiple sclerosis. Science of the Total Environment. 1980; 15(3): 261-8.

Ryan DE, Holzbecher J, Stuart DC. Trace elements in scalp-hair of persons with multiple sclerosis and of

normal individuals. Clin Chem. 1978; 24(11): 1996-2000. PMID: 709834.

Davies BE. Trace elements in the human environment: Problems and risks. Environ Geochem Health.

; 16(3-4): 97-106. doi: 10.1007/BF01747905. PMID: 24197203.

Van Horssen J, Schreibelt G, Drexhage J, Hazes T, Dijkstra CD, Van der Valk P, et al. Severe oxidative

damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic

Biol Med. 2008; 45(12): 1729-37. doi: 10.1016/j.freeradbiomed.2008.09.023. PMID: 18930811.

Polidoro G, Di Ilio C, Arduini A, La Rovere G, Federici G. Superoxide dismutase, reduced glutathione and

TBA-reactive products in erythrocytes of patients with multiple sclerosis. Int J Biochem. 1984; 16(5): 505- 9. doi: 10.1016/0020-711X(84)90167-8. PMID: 6724105.

Schreibelt G, Van Horssen J, Van Rossum S, Dijkstra CD, Drukarch B, de Vries HE. Therapeutic potential

and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology. Brain Res Rev.

; 56(2): 322-30. doi: 10.1016/j.brainresrev.2007.07.005. PMID: 17761296.

Clausen J, Jensen GE, Nielsen SA. Selenium in chronic neurologic diseases. Multiple sclerosis and Batten's

disease. Biol Trace Elem Res. 1988; 15: 179-203. doi: 10.1007/BF02990136. PMID: 2484516.

Socha K, Kochanowicz J, Karpinska E, Soroczynska J, Jakoniuk M, Mariak Z, et al. Dietary habits and

selenium, glutathione peroxidase and total antioxidant status in the serum of patients with relapsingremitting multiple sclerosis. Nutr J. 2014; 13: 62. doi: 10.1186/1475-2891-13-62. PMID: 24943732,

PMCID: PMC4080729.

Wikström J, Westermarcik T, Palo J. Selenium, vitamin E and copper in multiple sclerosis. Acta Neurol

Scand. 1976; 54(3): 287-90. doi: 10.1111/j.1600-0404.1976.tb04806.x. PMID: 961380.

Korpela H, Kinnunen E, Juntunen J, Kumpulainen J, Koskenvuo M. Serum selenium concentration,

glutathione peroxidase activity and lipid peroxides in a co-twin control study on multiple sclerosis. J

Neurol Sci. 1989; 91(1-2): 79-84. doi: 10.1016/0022-510X(89)90077-4. PMID: 2746294.

Waggoner DJ, Bartnikas TB, Gitlin JD. The role of copper in neurodegenerative disease. Neurobiol Dis.

; 6(4): 221-30. doi: 10.1006/nbdi.1999.0250. PMID: 10448050.

Aspli KT, Flaten TP, Roos PM, Holmoy T, Skogholt JH, Aaseth J. Iron and copper in progressive

demyelination-New lessons from Skogholt's disease. J Trace Elem Med Biol. 2015; 31: 183-7. doi:

1016/j.jtemb.2014.12.002. PMID: 25563774.

Masoud SA, Fakharian E. Assessment of serum magnesium, copper, and zinc levels in multiple sclerosis

(MS) patients. IJPBS. 2007; 1(2): 38-42.

Kapaki E, Segditsa J, Papageorgiou C. Zinc, copper and magnesium concentration in serum and CSF of

patients with neurological disorders. Acta Neurol Scand. 1989; 79(5): 373-8. doi: 10.1111/j.1600- 0404.1989.tb03803.x. PMID: 2545071.

Palm R, Hallmans G. Zinc and copper in multiple sclerosis. Journal of Neurology, Neurosurgery &

Psychiatry. 1982; 45(8): 691-8. doi: 10.1136/jnnp.45.8.691.

Gellein K, Skogholt JH, Aaseth J, Thoresen GB, Lierhagen S, Steinnes E, et al. Trace elements in

cerebrospinal fluid and blood from patients with a rare progressive central and peripheral demyelinating

disease. J Neurol Sci. 2008; 266(1-2): 70-8. doi: 10.1016/j.jns.2007.08.042. PMID: 17900623.

Sedighi B, Ebrahimi HA, Haghdoost AA, Abotorabi M. Comparison of serum levels of copper and zinc

among multiple sclerosis patients and control group. Iran J Neurol. 2013; 12(4): 125-8. PMID: 24250921,

PMCID: PMC3829305.

Mana P, Fordham SA, Staykova MA, Correcha M, Silva D, Willenborg DO, et al. Demyelination caused

by the copper chelator cuprizone halts T cell mediated autoimmune neuroinflammation. J Neuroimmunol.

; 210(1-2): 13-21. doi: 10.1016/j.jneuroim.2009.02.013. PMID: 19344958.

Hwang YM, Stathopulos PB, Dimmick K, Yang H, Badiei HR, Tong MS, et al. Nonamyloid aggregates

arising from mature copper/zinc superoxide dismutases resemble those observed in amyotrophic lateral

sclerosis. J Biol Chem. 2010; 285(53): 41701-11. doi: 10.1074/jbc.M110.113696. PMID: 20974846,

PMCID: PMC3009897.

Choi BY, Jang BG, Kim JH, Seo JN, Wu G, Sohn M, et al. Copper/zinc chelation by clioquinol reduces

spinal cord white matter damage and behavioral deficits in a murine MOG-induced multiple sclerosis

model. Neurobiol Dis. 2013; 54: 382-91. doi: 10.1016/j.nbd.2013.01.012. PMID: 23360710.

Torkildsen O, Brunborg LA, Myhr KM, Bø L. The cuprizone model for demyelination. Acta Neurol Scand

Suppl. 2008; 188: 72-6. doi: 10.1111/j.1600-0404.2008.01036.x. PMID: 18439226.

Tezuka T, Tamura M, Kondo MA, Sakaue M, Okada K, Takemoto K, et al. Cuprizone short-term exposure:

astrocytic IL-6 activation and behavioral changes relevant to psychosis. Neurobiol Dis. 2013; 59: 63-8. doi:

1016/j.nbd.2013.07.003. PMID: 23867234, PMCID: PMC3936339.

Jackson M, Al‐Chalabi A, Enayat ZE, Chioza B, Leigh PN, Morrison KE. Copper/zinc superoxide

dismutase 1 and sporadic amyotrophic lateral sclerosis: Analysis of 155 cases and identification of novel

insertion mutation. Ann Neurol. 1997; 42(5): 803-7. doi: 10.1002/ana.410420518. PMID: 9392581.

Alimonti A, Ristori G, Giubilei F, Stazi MA, Pino A, Visconti A, et al. Serum chemical elements and

oxidative status in Alzheimer's disease, Parkinson disease and multiple sclerosis. Neurotoxicology. 2007;

(3): 450-6. doi: 10.1016/j.neuro.2006.12.001. PMID: 17267042.

Johnson S. The possible role of gradual accumulation of copper, cadmium, lead and iron and gradual

depletion of zinc, magnesium, selenium, vitamins B2, B6, D, and E and essential fatty acids in multiple

sclerosis. Med Hypotheses. 2000; 55(3): 239-41. doi: 10.1054/mehy.2000.1051. PMID: 10985916.

Swaminathan R. Magnesium metabolism and its disorders. Clin Biochem Rev. 2003; 24(2): 47-66. PMID:

, PMCID: PMC1855626.

Yasui M, Yase Y, Ando K, Adachi K, Mukoyama M, Ohsugi K. Magnesium concentration in brains from

multiple sclerosis patients. Acta Neurol Scand. 1990; 81(3): 197-200. doi: 10.1111/j.1600- 0404.1990.tb00965.x. PMID: 2353567.

Deluca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J. 2001; 15(14): 2579-85.

doi: 10.1096/fj.01-0433rev. PMID: 11726533.

Bhalla AK, Amento EP, Clemens TL, Holick MF, Krane SM. Specific high-affinity receptors for 1, 25- dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction

in T lymphocytes following activation. J Clin Endocrinol Metab. 1983; 57(6): 1308-10. doi: 10.1210/jcem- 57-6-1308. PMID: 6313738.

Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1, 25-dihydroxyvitamin D3 receptors in human

leukocytes. Science. 1983; 221(4616): 1181-3. doi: 10.1126/science.6310748. PMID: 6310748.

Harrison HE. Parathyroid hormone and vitamin D. Yale J Biol Med. 1966; 38(5): 393-409. PMID:

, PMCID: PMC2591202.

Vetter T, Lohse MJ. Magnesium and the parathyroid. Curr Opin Nephrol Hypertens. 2002; 11(4): 403-10.

doi: 10.1097/00041552-200207000-00006. PMID: 12105390.

Published

2022-03-07

Issue

Section

Articles